BioSpace News Archive

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022 at 9:40 a.m. ET.

Icosavax, Inc. (Nasdaq: ICVX) today announced that the company will participate in and host one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference taking place November 29 through December 1, 2022.

Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team will host an investor event to provide a data update that will include preliminary data from the six-month follow-up of the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® in anti-PD1 failed melanoma.

Congruence Therapeutics announced today the appointment of Sharath S. Hegde, Ph.D. as Chief Scientific Officer.

Ardelyx, Inc. today announced that management will participate in a fireside discussion at the 34th Annual Piper Sandler Healthcare Conference.

MAIA Biotechnology, Inc. announced today that certain officers and directors of the Company, including Founder and Chief Executive Officer Vlad Vitoc, M.D., and leading investor and Board Member Stan Smith, Ph.D., plan to initiate additional investing in the Company’s common stock.

As radiology departments face challenges in a new era of healthcare, GE Healthcare imaging solutions are designed to support clinicians in meeting competing demands for their time and enable greater focus on patient care.

Crown Aesthetics, a Crown Laboratories, Inc. company, maintains its position at the forefront of skincare innovation with the unveiling of a new study in the Journal of Cosmetic Dermatology showcasing the efficacy of its patented Xycrobe® technology, formulated to address the often overlooked skin biome.

Waters Corporation announced a new Per-and Polyfluoroalkyl Substances quantitation workflow enabled by enhancements to its waters_connect™ for quantitation software.

VBI Vaccines Inc. today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were presented at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), on Friday, November 18, 2022.